Ausgabe 3/2016
Inhalt (10 Artikel)
Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic
Kinga Majchrzak, Michelle H. Nelson, Stefanie R. Bailey, Jacob S. Bowers, Xue-Zhong Yu, Mark P. Rubinstein, Richard A. Himes, Chrystal M. Paulos
Identification of the murine H-2Db and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes
Shiwen Peng, Austin Mattox, Simon R. Best, Anca M. Barbu, James A. Burns, Belinda Akpeng, Jessica Jeang, Benjamin Yang, Eiichi Ishida, Chien-Fu Hung, Tzyy-Choou Wu, Sara I. Pai
The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib
Annkristin Heine, Judith Schilling, Barbara Grünwald, Achim Krüger, Heidrun Gevensleben, Stefanie Andrea Erika Held, Natalio Garbi, Christian Kurts, Peter Brossart, Percy Knolle, Linda Diehl, Bastian Höchst
Cathepsin G-mediated proteolytic degradation of MHC class I molecules to facilitate immune detection of human glioblastoma cells
David Palesch, Johanna Wagner, Annika Meid, Nicole Molenda, Marcin Sienczyk, Jutta Burkhardt, Jan Münch, Lea Prokop, Stefan Stevanovic, Mike-Andrew Westhoff, Marc-Eric Halatsch, Christian Rainer Wirtz, Michal Zimecki, Timo Burster
TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors
Timothy T. Spear, Glenda G. Callender, Jeffrey J. Roszkowski, Kelly M. Moxley, Patricia E. Simms, Kendra C. Foley, David C. Murray, Gina M. Scurti, Mingli Li, Justin T. Thomas, Alexander Langerman, Elizabeth Garrett-Mayer, Yi Zhang, Michael I. Nishimura
Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155
Baofu Zhang, Weina Zhao, Huizhong Li, Yuanyuan Chen, Hui Tian, Liantao Li, Longzhen Zhang, Chao Gao, Junnian Zheng
The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity
Daphné Laubreton, Sylvie Bay, Christine Sedlik, Cécile Artaud, Christelle Ganneau, Edith Dériaud, Sophie Viel, Anne-Laure Puaux, Sebastian Amigorena, Catherine Gérard, Richard Lo-Man, Claude Leclerc
Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity
Kalijn F. Bol, Erik H. J. G. Aarntzen, Jeanette M. Pots, Michel A. M. Olde Nordkamp, Mandy W. M. M. van de Rakt, Nicole M. Scharenborg, Annemiek J. de Boer, Tom G. M. van Oorschot, Sandra A. J. Croockewit, Willeke A. M. Blokx, Wim J. G. Oyen, Otto C. Boerman, Roel D. M. Mus, Michelle M. van Rossum, Chantal A. A. van der Graaf, Cornelis J. A. Punt, Gosse J. Adema, Carl G. Figdor, I. Jolanda M. de Vries, Gerty Schreibelt
Requirement of interleukin 7 signaling for anti-tumor immune response under lymphopenic conditions in a murine lung carcinoma model
Toshihiro Suzuki, Hidehiro Kishimoto, Ryo Abe
Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway
Davide Bommarito, Allison Martin, Edouard Forcade, Maria-Dorothea Nastke, Jerome Ritz, Roberto Bellucci